Core Viewpoint - Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, reported its preliminary results for the year ended December 31, 2025, focusing on innovative treatments for gastrointestinal cancers and type 1 diabetes [3][11]. Company Overview - Biodexa is headquartered in Cardiff, UK, and is listed on NASDAQ under the ticker BDRX. The company is developing products targeting gastrointestinal cancers, including Familial Adenomatous Polyposis (FAP) and Gastrointestinal Stromal Tumors (GIST) [3][11]. - The lead development programs include eRapa for FAP and Non-Muscle Invasive Bladder Cancer, MTX240 for GIST, and tolimidone for type 1 diabetes [3][11][12]. Development Pipeline - The company has transitioned from a drug delivery focus to a therapeutics company, with all pipeline assets currently at the clinical stage [12]. - The development pipeline includes: - eRapa: undergoing a Phase 3 trial for FAP and a Phase 2 study for Non-Muscle Invasive Bladder Cancer [16][19]. - MTX240: in-licensed from Otsuka, ready for Phase 1 studies targeting GIST [12][38]. - Tolimidone: in Phase 2a for type 1 diabetes, with potential disease-modifying effects [31][42]. Clinical Trials and Milestones - In 2025, significant milestones included the initiation of the Phase 3 Serenta trial for eRapa, with 168 patients expected to be enrolled across multiple sites in the US and Europe [23][37]. - The company received FDA Fast Track designation and Orphan Drug Designation for eRapa, enhancing its development prospects [37]. - The first patient in the Phase 3 trial was enrolled in August 2025, with European enrollment commencing in December 2025 [36][37]. Financial Overview - R&D expenditure for 2025 was £3.96 million, a decrease of 27.2% from £5.44 million in 2024, reflecting a strategic focus on key projects [53][55]. - The company reported a net cash inflow of £6.87 million for the year, compared to a net outflow of £4.30 million in 2024, indicating improved financial management [62][65]. - Administrative costs increased to £4.84 million, driven by professional fees and foreign exchange movements [56]. Market Potential - The global GIST market is valued at approximately $1.3 billion, with an expected growth rate of 6-10% annually through 2032, driven by rising incidence and new therapeutic options [28]. - There is a significant unmet medical need for GIST patients who develop resistance to existing treatments, positioning MTX240 as a potential solution [27][39]. Strategic Partnerships and Financing - The company entered a License and Collaboration Agreement with Otsuka for MTX240, which includes exclusive global development rights, excluding Japan [38]. - Biodexa secured a $20 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the Phase 3 program for eRapa, contingent on a company match [46][74].

Core Insights - Biodexa Pharmaceuticals has launched a Global Early Access Program for eRapa, aimed at patients with Familial Adenomatous Polyposis (FAP), through a partnership with Tanner Pharma Group [1][2][3] Company Overview - Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative treatments for gastrointestinal cancers [1][7] - The company is headquartered in Cardiff, UK, and has a lead development program for eRapa, which is under development for FAP and Non-Muscle Invasive Bladder Cancer [7][11] Product Information - eRapa is an oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor, which plays a significant role in cellular metabolism, growth, and proliferation [4][8] - The rationale for using eRapa in treating FAP is supported by the over-expression of mTOR in FAP polyps [4][8] Clinical Development - Biodexa has initiated a double-blind, placebo-controlled Phase 3 trial for eRapa, planning to enroll 168 patients across 30 clinical sites in the US and Europe, with a 2:1 randomization of drug to placebo [4] - The Phase 3 program is backed by a $20 million grant from the Cancer Prevention and Research Institute of Texas [4] Market Context - FAP is characterized by a proliferation of polyps in the colon and/or rectum, typically occurring in mid-teens, with no currently approved therapeutic options available [3] - The incidence of FAP is reported to be one in 5,000 to 10,000 in the US and one in 11,300 to 37,600 in Europe [3] Strategic Partnership - The partnership with Tanner Pharma Group aims to provide ethical access to eRapa for FAP patients globally, subject to local regulations and funding availability [2][5]

Core Insights - Biodexa Pharmaceuticals has launched a Global Early Access Program for eRapa, aimed at providing this investigational treatment to patients with Familial Adenomatous Polyposis (FAP) through a partnership with Tanner Pharma Group [1][2][3] Group 1: Company Overview - Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative treatments for gastrointestinal cancers [1] - The company’s lead development programs include eRapa for FAP and Non-Muscle Invasive Bladder Cancer, MTX240 for Gastrointestinal Stromal Tumors, and tolimidone for type 1 diabetes [7] Group 2: eRapa Details - eRapa is an oral capsule formulation of rapamycin, an mTOR inhibitor, which plays a significant role in cellular metabolism, growth, and proliferation [4][8] - The drug has received Orphan Designation in the US, with plans to seek similar designation in Europe, and is based on the rationale that mTOR is over-expressed in FAP polyps [3][4] Group 3: Early Access Program - The Early Access Program will allow clinicians globally to prescribe eRapa to appropriate FAP patients, subject to local regulations and funding availability [2] - Biodexa aims to generate Real World Data to enhance understanding of the challenges faced by FAP patients [2] Group 4: Clinical Trials - A double-blind, placebo-controlled Phase 3 trial for eRapa is planned, involving 30 clinical sites across the US and Europe, with an enrollment target of 168 patients in a 2:1 randomization [4] - The Phase 3 program is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas [4] Group 5: Tanner Pharma Group - Tanner Pharma Group is a specialist pharmaceutical services provider that focuses on improving global access to medicines, supporting manufacturers in providing compliant access to innovative treatments [5]

Core Insights - Biodexa Pharmaceuticals PLC has announced its support for the Life's a Polyp Foundation, the first U.S. patient advocacy group dedicated to Familial Adenomatous Polyposis (FAP) patients, through an initial financial grant [2][3][4] - The Life's a Polyp Foundation aims to provide resources, community support, and awareness for families affected by FAP, a genetic condition that leads to a high risk of colorectal cancer [3][10] - Biodexa's lead program, eRapa, is currently in a Phase 3 trial and represents a potential non-surgical treatment for FAP, with over 20% of patients already enrolled and having received Fast Track designation from the FDA [4][6] Company Overview - Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative treatments for gastrointestinal cancers, including FAP and Non-Muscle Invasive Bladder Cancer [5] - The company is also developing MTX240 for Gastrointestinal Stromal Tumors (GIST) and tolimidone for type 1 diabetes, showcasing a diverse pipeline of therapeutic candidates [5][8] Product Details - eRapa is an oral capsule formulation of rapamycin, an mTOR inhibitor, which plays a significant role in cellular metabolism and tumorigenesis [6] - MTX240 functions as a molecular glue that stabilizes specific proteins in GIST cancer cells, promoting apoptosis through a unique mechanism [7] - Tolimidone is a selective inhibitor of Lyn kinase, showing potential for glycaemic control in diabetes models [8]

Core Viewpoint - MTX240's unique mechanism may provide a significant advantage in treating gastrointestinal stromal tumors (GIST), particularly for patients resistant to current therapies [1][2]. Group 1: Company Overview - Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare diseases, with a growing emphasis on gastrointestinal cancers [1]. - The company has introduced MTX240, a new candidate targeting GIST, which is now phase 1-ready [1]. Group 2: Mechanism of Action - MTX240 employs a unique molecular glue mechanism that distinguishes it from existing treatments, potentially benefiting a wider range of GIST patients, including those with TKI-resistant disease [2]. - Unlike TKIs that often fail due to tumor cell mutations, MTX240 is designed to remain effective regardless of secondary mutations in GIST [3]. Group 3: Preclinical Success - In preclinical PDX models, MTX240 showed dose-dependent efficacy in reducing GIST tumors, both in non-resistant and TKI-resistant cases [4]. - If clinical trials confirm these preclinical results, MTX240 could be co-administered with TKIs or even replace them entirely [5]. Group 4: Regulatory and Market Potential - MTX240 is eligible for Orphan Drug designation in the U.S. and EU, granting it market exclusivity for seven and ten years, respectively, upon approval [5]. - The drug has Composition of Matter patents extending through 2037, enhancing its market potential [5]. Group 5: Licensing and Financial Aspects - Biodexa has secured exclusive worldwide rights to MTX240, excluding Japan, with a modest upfront fee and development milestones included in the licensing deal [6]. - The agreement also involves low double-digit approval milestones and mid single-digit tiered royalties [6].

Core Viewpoint - Biodexa Pharmaceuticals has secured an exclusive license for OPB-171775, a novel molecular glue aimed at treating gastrointestinal stromal tumors (GIST), which is expected to address significant unmet medical needs in patients resistant to current therapies [1][12]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for rare diseases with unmet medical needs [14]. - The company is advancing a pipeline that includes eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, alongside MTX240 [14][16]. Product Details - MTX240, also known as OPB-171775, utilizes a unique molecular glue mechanism to induce targeted protein interactions, distinguishing it from conventional kinase inhibitors [3]. - The compound targets GIST by stabilizing SLFN12, which promotes apoptosis in cancer cells through a pathway independent of KIT signaling, potentially overcoming resistance mechanisms associated with existing therapies [5]. Clinical Rationale - GIST is primarily driven by mutations in the KIT receptor tyrosine kinase, with current treatments often leading to resistance due to secondary mutations or alternative signaling pathways [4]. - Approximately 10-15% of GIST patients are either primarily refractory or develop secondary resistance to available TKIs, highlighting the need for new therapeutic options [10]. Efficacy Evidence - In patient-derived xenograft (PDX) models, MTX240 demonstrated dose-dependent anti-tumor efficacy in TKI-resistant scenarios, regardless of KIT mutation status [6][9]. - The PDX models used in studies are more predictive of human clinical outcomes, bridging laboratory findings with potential clinical applications [9]. Market Potential - The global GIST market is valued at approximately USD 1.3 billion, with an expected annual growth rate of 6-10% through 2032, driven by increasing incidence and new treatment options for resistant cases [11]. - GIST qualifies for orphan drug designation, which may provide regulatory advantages and incentives for drug development [11]. Licensing Agreement - Under the licensing agreement, Biodexa holds exclusive rights to develop and commercialize MTX240 globally, except in Japan, where Otsuka retains rights [12]. - The agreement includes an upfront fee, development milestones, and tiered royalties on net sales in the mid-single digit range [12]. Intellectual Property - MTX240 is protected by composition of matter patents in the US, Europe, Japan, and other countries, extending through 2037 without any patent term extension [13].

Core Viewpoint - Biodexa Pharmaceuticals has secured an exclusive license for OPB-171775, a novel molecular glue aimed at treating gastrointestinal stromal tumors (GIST), which may also have applications in other indications [1][2]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for rare diseases with unmet medical needs [1][13]. - The company is advancing its pipeline, which includes MTX240 (OPB-171775) and eRapa, targeting conditions such as Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer [2][13]. Product Details - MTX240 utilizes a unique molecular glue mechanism that facilitates targeted protein interactions, distinguishing it from conventional kinase inhibitors [3]. - The compound targets GIST driven by mutations in the KIT receptor tyrosine kinase, addressing the challenge of resistance that often develops with existing tyrosine kinase inhibitors (TKIs) [4][5]. Clinical Rationale - MTX240 has demonstrated dose-dependent anti-tumor efficacy in patient-derived xenograft (PDX) models resistant to imatinib and sunitinib, regardless of KIT mutation status [6][8]. - The mechanism of action involves stabilizing SLFN12 to induce apoptosis in GIST cells through a pathway independent of KIT signaling, potentially benefiting a significant proportion of GIST patients [5][9]. Market Opportunity - GIST affects approximately 3,000-4,000 patients annually in the U.S., with 10-15% of patients experiencing resistance to available TKIs, highlighting a substantial unmet medical need [9]. - The global GIST market is valued at around USD 1.3 billion and is projected to grow at an annual rate of 6-10% through 2032, driven by increasing incidence and new therapeutic options [10]. Licensing Agreement - Biodexa has exclusive global rights to develop and commercialize MTX240, except in Japan where Otsuka retains rights. The agreement includes an upfront fee, development milestones, and tiered royalties on net sales [11]. Intellectual Property - MTX240 is protected by composition of matter patents in the U.S., Europe, Japan, and other countries, extending through 2037 without any patent term extension [12].

Core Viewpoint - Biodexa Pharmaceuticals PLC has appointed Fiona Sharp as Chief Financial Officer and Company Secretary, promoting her to the Board of Directors, effective immediately [2][4]. Group 1: Leadership Changes - Fiona Sharp has been with Biodexa since December 2019, initially serving as Group Financial Controller, and has expanded her responsibilities to include many CFO duties [3]. - Stephen Stamp will step down from his roles as CFO and Company Secretary but will continue as Chief Executive Officer [4]. Group 2: Company Background - Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [5]. - The company's lead development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [5]. Group 3: Product Development - eRapa is an oral capsule formulation of rapamycin, an mTOR inhibitor that plays a significant role in cellular metabolism and tumorigenesis [6]. - Tolimidone is a selective inhibitor of Lyn kinase, showing potential as a first-in-class blood glucose modulating agent [6]. - MTX110 is a formulation of panobinostat designed for direct delivery to tumors, bypassing the blood-brain barrier to reduce systemic toxicity [7]. Group 4: Company Capabilities - Biodexa is supported by three proprietary drug delivery technologies aimed at enhancing the bio-delivery and bio-distribution of medicines [8].

Core Viewpoint - Biodexa Pharmaceuticals PLC has announced a public offering priced at $10 million, aimed at funding its development programs and general corporate purposes [2][3]. Offering Details - The offering consists of 157,000 ADS Units, each comprising one American depositary share (representing 100,000 ordinary shares) and two Series L warrants [2]. - Additionally, there are 2,891,781 Pre-Funded Units, each consisting of one pre-funded warrant to purchase one ADS and two Series L Warrants [2]. - The public offering price for each ADS Unit is set at $3.28, while each Pre-Funded Unit is priced at $3.2799 [2]. Financial Proceeds - The expected gross proceeds from the offering, before deducting fees and expenses, are approximately $10 million [3]. - The net proceeds will be utilized for development programs, working capital, and other corporate purposes [3]. Closing and Agent Information - The offering is anticipated to close on December 19, 2025, pending customary closing conditions [4]. - Maxim Group LLC is acting as the sole placement agent for this offering [4]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [7]. - The company's lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [7]. Product Details - eRapa is an oral formulation of rapamycin, an mTOR inhibitor involved in cellular metabolism and tumorigenesis [8]. - Tolimidone is a selective inhibitor of Lyn kinase, showing potential for glycaemic control in diabetes [9]. - MTX110 is a formulation of panobinostat designed for direct delivery to tumors, bypassing the blood-brain barrier [10][11].

Registration No. 333-291598 As filed with the U.S. Securities and Exchange Commission on December 11, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (IRS Em ...